Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Supportive Care in Cancer
Erschienen in: Supportive Care in Cancer 7/2018

29.03.2018 | Review Article

Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis

verfasst von: Baoqi Duan, Jinsong Xie, Qinglin Rui, Wenxi Zhang, Zhaoqing Xi

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Shengmai injection (SMI) has shown promising outcomes in the management of non-small cell lung cancer (NSCLC). This meta-analysis aimed to investigate the add-on effects of SMI to chemotherapy in NSCLC patients.

Methods

A comprehensive literature search was performed in the Cochrane Library, PubMed, Embase, CNKI, VIP, and Wanfang up to December 2017. Only randomized controlled trials (RCTs) evaluating SMI in combination with chemotherapy versus chemotherapy alone in NSCLC patients were eligible. The outcome measures were quality of life, chemotherapy-induced grade 3/4 myelosuppression or gastrointestinal reactions, and objective tumor response (equals complete response plus partial response). Pooled risk ratio (RR) with 95% confidence interval (CI) was used to evaluate dichotomous and continuous outcome, respectively.

Results

A total of 15 RCTs were included and analyzed. Meta-analysis showed that SMI combined with chemotherapy was associated with a significant improvement in Karnofsky Performance Status (RR 2.36; 95% CI 1.50–3.96) compared with the chemotherapy alone. Moreover, adjunctive treatment with SMI significantly reduced grade 3/4 myelosuppression (RR 0.61; 95% CI 0.46–0.81) and gastrointestinal reactions (RR 0.64; 95% CI 0.46–0.90). However, there was no significant difference in objective tumor response (RR 1.17; 95% CI 0.99–1.37) between two groups.

Conclusions

SMI add-on therapy appeared to be more effective in improving quality of life and reducing chemotherapy-induced adverse effects. However, more well-designed RCTs are warranted to confirm the findings of this meta-analysis because of the suboptimal methodological quality of the included trials.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc 83(5):584–594CrossRefPubMed
3.
Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L (2017) Lung cancer: current therapies and new targeted treatments. Lancet 389(10066):299–311CrossRefPubMed
4.
Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D’Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M (2017) Non-small cell lung Cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 15(4):504–535CrossRef
5.
6.
Jiao L, Dong C, Liu J, Chen Z, Zhang L, Xu J, Shen X, Che J, Yang Y, Huang H, Li H, Sun J, Jiang Y, Mao Z, Chen P, Gong Y, Jin X, Xu L (2017) Effects of Chinese medicine as adjunct medication for adjuvant chemotherapy treatments of non-small cell lung cancer patients. Sci Rep 7:46524CrossRefPubMedPubMedCentral
7.
Han Y, Wang H, Xu W, Cao B, Han L, Jia L, Xu Y, Zhang Q, Wang X, Zhang G, Yu M, Yang G (2016) Chinese herbal medicine as maintenance therapy for improving the quality of life for advanced non-small cell lung cancer patients. Complement Ther Med 24:81–89CrossRefPubMed
8.
Jiang Y, Liu LS, Shen LP, Han ZF, Jian H, Liu JX, Xu L, Li HG, Tian JH, Mao ZJ (2016) Traditional Chinese medicine treatment as maintenance therapy in advanced non-small-cell lung cancer: a randomized controlled trial. Complement Ther Med 24:55–62CrossRefPubMed
9.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(4):264–269 W264CrossRefPubMed
10.
Schag CC, Heinrich RL, Ganz PA (1984) Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 2(3):187–193CrossRefPubMed
11.
Ramalingam S, Belani CP (2002) Doublet chemotherapy for advanced non-small cell lung cancer. Clin Lung Cancer 4(1):13PubMed
12.
Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214CrossRefPubMed
13.
Zhou GF, Li AJ (2003) Shengmai injection treatment for chemotherapy-reduced adverse reaction in non-small cell lung cancer 30 cases of patients. CJITWM 23(3):231–232
14.
Li GX (2005) Clinical observation of Shengmai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer. JETCM 14(3):233–234
15.
Wang R, Wang ZX, Wang QC (2006) Shengmai injection combined with gemcitabine plus cisplatin cure advanced NSCLC. Suzhou Univ J Med Sci 26(4):631–633
16.
Liang CW (2007) Clinical study on the treatment of advanced NSCLC with Shengmai injection combined with chemotherapy. J Anhui TCM Coll 26(3):15–18
17.
Yao JT, Wang YZ, Zhang YJ, Wu HM, Zhao Z (2007) Clinical observation of Shengmai injection combined chemotherapy in advanced lung cancer. J Mod Oncol 15(8):1119–1120
18.
Zhang QH (2008) Clinical observation of adjunctive treatment with Shengmai injection in non small cell lung cancer. Mod J Integr Tradit Chin West Med 17(24):3827–3828
19.
Sun DB, Han Y (2009) The VEGF levels after pulse-activating ingection combined with interventional chemotherapy for non-small cell lung cancer. J Xinjiang Med Univ 32(9):1282–1284
20.
Chen QS, Chen Y, Yang ZJ, Liu JB, Pei RQ (2011) The effect on quality of life to advanced stage non-small cell lung cancer patient treated with Shengmai injection combined chemotherapy. China J Chin Med 26(1):13–15
21.
Lu XA (2011) Effect of Shengmai injection combined with chemotherapy on the quality of life and immune function in patients with advanced non-small cell lung cancer. Shaanxi J Tradit Chin Med 32(4):389–391
22.
Bao YH (2011) Effect of Shengmai injection on the quality of life of patients with advanced non-small cell lung cancer receiving chemotherapy. Chin J Clin Res 24(11):1037–1038
23.
Yang ZJ, Deng CM, Qiu YH, Mo BS (2012) Shengmai injection combined with NP regimen in the treatment of 30 cases of advanced non-small cell lung cancer. World Health Dig Med Periodieal 9(26):124–125
24.
Wu Q, He X (2012) Clinical observation of Shengmai injection combined with chemotherapy in the treatment of middle to advanced lung cancer. Chin J Tradit Med Sci Technol 19(1):71–72
25.
Wang DJ (2012) Efficacy of Shengmai injection combined with TP regimen in the treatment of advanced non-small cell lung cancer. Jilin Med J 33(11):2315–2316
26.
Liu JY, Liu BY, Liu Y (2014) Clinical efficacy of Shengmai injection combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. China J Pharm Econ 9(11):211–212
27.
Zhang CM (2016) Effect of Shengmai injection combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer. Chin Prim Health Care 30(7):92–93
28.
Mannion E, Gilmartin JJ, Donnellan P, Keane M, Waldron D (2014) Effect of chemotherapy on quality of life in patients with non-small cell lung cancer. Support Care Cancer 22(5):1417–1428CrossRefPubMed
29.
Li Q, Liu H (2005) Pharmacological action and clinical application of Shengmai injection. Med Recapitulate 11(10):950–952
Metadaten
Titel
Effects of Shengmai injection add-on therapy to chemotherapy in patients with non-small cell lung cancer: a meta-analysis
verfasst von
Baoqi Duan
Jinsong Xie
Qinglin Rui
Wenxi Zhang
Zhaoqing Xi
Publikationsdatum
29.03.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2018
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-018-4167-4

Weitere Artikel der Ausgabe 7/2018

Supportive Care in Cancer 7/2018 Zur Ausgabe

Commentary

Sestrin family of genes and their role in cancer-related fatigue

Original Article

Head and neck cancer patient experience of a new dietitian-delivered health behaviour intervention: ‘you know you have to eat to survive’

Original Article

Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT)

Review Article

Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review

Original Article

Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer

Original Article

Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise